[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
March 15, 2000

Sources of Bias in the Economic Analysis of New Drugs—Reply

Author Affiliations

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(11):1423-1424. doi:10.1001/jama.283.11.1421

In Reply: We agree with Dr Gagnon that it is only rational for pharmaceutical firms to support positive economic analyses, although that does not preclude conflict of interest. It should also be noted that the perspective of our study is from the scientific community, not from the pharmaceutical industry. We found that fewer studies with negative results are sponsored by pharmaceutical firms, which leads to a bias in the available economic literature for these drugs. As Dr Le Pen notes, pharmacoeconomic research (and medical research in general) would benefit from the publication of studies with both positive and negative results.

First Page Preview View Large
First page PDF preview
First page PDF preview